Loading quotes...

Forecast

The analysts' average price target is €71.11 (+5.82%). The median is €76.65 (+14.06%).

Buy	14
Hold	10
Sell	2

Discussions in the community

There is no discussion about this asset yet.

Start discussion

News Go to news feed

Alcon acquires Neurotech for $550 million and bolsters retina business with Encelto

Alcon has acquired Neurotech Pharmaceuticals for $550 million and may make additional success‑based payments. The deal adds Encelto to its retina portfolio — the only therapy approved in the U.S. for MacTel type 2 — addressing around 25,000 diagnosed patients in the U.S. Neurotech brings encapsulated cell therapies for chronic and neurodegenerative eye diseases. Alcon expects slight revenue growth in 2027 and a temporary hit to adjusted earnings per share, after which the acquisition is expected to be accretive. » More on finanzen.net
Alcon launches surgical microscope Unity M

Alcon has introduced the modular surgical microscope “Unity M” for eye surgery, which is said to provide a more stable view through an improved red reflex zone and adjustable color illumination. The device is approved in the US, Japan, Canada, India and Europe; deliveries began in September with the market launch first in the US and Japan, and later in Europe. The stock reacted with an intraday decline of around 1 percent. » More on finanzen.net
Alcon places €500 million bond at 3.875% due 2033

Alcon, through its subsidiary Alcon Finance Corporation, is issuing a five‑year €500 million bond with a 3.875% coupon. The bond will be listed on the Luxembourg Stock Exchange and traded on the Euro MTF; closing of the transaction is scheduled for 2 September. Proceeds are to be used for general corporate purposes, including wholly or partly refinancing existing debt. » More on finanzen.net
Alcon places €500 million bond with 3.875% coupon due 2033

Alcon announced the placement of a senior bond of €500 million maturing in 2033 with a coupon of 3.875%. The bonds are being issued by Alcon Finance Corporation and are secured by a senior guarantee from Alcon Inc. An admission to trading on the Luxembourg Stock Exchange and on the Euro MTF has been applied for; the closing of the issue is scheduled for 2 September 2026. Proceeds will be used for general corporate purposes, including possible refinancing of existing debt. » More on de.investing.com
SGA exits Alcon as cataract demand weakens and competition increases

Sustainable Growth Advisers (SGA) exited its position in Alcon, citing subdued cataract and contact lens markets and rising competition in premium intraocular lenses that is eroding Alcon’s market share. Despite Alcon’s 6% constant-currency revenue growth and 16%+ EPS growth in Q1 and strong product launches, SGA gradually reduced the holding and redeployed capital into Schneider Electric to pursue higher growth. SGA views Alcon as a market leader but trimmed exposure due to near-term demand pressures and increased competitive risk. » More on finance.yahoo.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, Alcon has already paid €0.31 in dividends. The last payout was in May.

Financials

In the last quarter, Alcon had revenue of €2.42bn and net profit of €229.54m

(EUR)	September 2026	YoY
Revenue	2.42bn	8.48%
Gross profit	1.43bn	15.26%
Net profit	229.54m	13.66%
EBITDA	596.81m	5.39%

Fundamentals

Metric	Value
Market capitalization	€31.5bn
Number of shares	483.4m
52-week high/low	€79.50 - €56.09
Dividend yield	0.47%
Dividends TTM	€0.31
Beta	0.72
P/E ratio	52.82
PEG ratio	-1.47
P/B ratio	1.59
P/S ratio	3.18

Company profile

Alcon Inc., an eye care company, researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for use in surgical procedures. Its cataract products include centurion vision system, LenSx femtosecond laser, LuxOR surgical ophthalmic microscope, NGENUITY 3D visualization system, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantables products, including AcrySof IQ IOLs products include monofocal IOLs and advanced technology IOLs under the PanOptix and ReSTOR brands for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glaucoma, contact lens care, and ocular allergies; and ocular vitamins and redness relievers under the TOTAL, PRECISION, DAILIES AquaComfort PLUS, Air Optix, Opti-Free, Clear Care, Tears Naturale, Genteal, ICAPS, and Vitalux brands. The company was formerly known as Alcon Universal S.A. and changed the name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.

Name	Alcon
CEO	David J. Endicott
Headquarters	Geneva, ge Switzerland
Website	alcon.com
Sector	Health Care
Industry	Health Care Technology
IPO	09/04/2019
Employees	25,942